|
||||||||||||||||||
|
|
| Upcoming Programs | ||||||
|
|
||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||
Overview
This CME activity will provide primary care clinicians with the tools needed to better understand rotavirus prevention and management. The goal of this educational activity is to provide primary care clinicians with the education to work toward decreasing the overall impact of rotavirus in the US.
Objectives
Expand clinician knowledge of the safety and efficacy of the rotavirus vaccine and risk benefits and increase the level of effective management of rotavirus for those patients who have not received the vaccine
Describe the ages at which it is appropriate to administer the rotavirus vaccine and name one method to help prevent rotavirus transmission within the home setting
Faculty
Penelope H. Dennehy, MD
Director, Pediatric Infectious Diseases
Hasbro ChildrenŐs Hospital
Professor of Pediatrics
Warren Alpert Medical School of Brown University
Rhode Island Hospital
Providence, RI
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. As HPV is most prevalent among young, sexually active individuals, prevention through prophylactic HPV vaccination of preadolescents and adolescents before they become sexually active provides the maximum health benefit. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection, provide an update on the safety and efficacy of HPV vaccines, including recent data to expand the benefits of vaccination, and address common barriers to implementing HPV vaccination into pediatric practice.
Objectives
Describe the health consequences associated with HPV infection
Discuss the benefits of HPV vaccination with adolescent patients and their parents
Faculty
J. Dennis Fortenberry, MD, MS
Professor of Pediatrics
Indiana University School of Medicine
Indianapolis, IN
Lawrence J. D'Angelo, MD, MPH
Chief, Division of Adolescent and Young Adult Medicine
Children's National Medical Center
Washington, DC
Overview
This educational activity is designed to give clinicians an overview of asthma as a heterogeneous disease and its implication for individual treatment. It will also provide guidance for using the NAEPP EPR 3 guidelines as part of a comprehensive, long-term asthma management plan custom tailored for the needs of each individual patient. NAEPP EPR 3 domains of asthma control include measures of assessment and monitoring; control of factors that contribute to asthma severity; pharmacologic therapy; and education for a partnership in asthma.
Objectives
Understand why the updated NAEPP EPR 3 guidelines are useful in treatment of pediatric patients with asthma and name the 2 domains for assessing asthma control
Name the symptoms of asthma and understand how to effectively monitor their asthma patients by naming the specific time intervals to ensure that patients maintain optimal control
Faculty
Sergei N. Belenky, MD, PhD
Clinical Assistant Professor of Medicine
Rheumatology and Clinical Immunology
University of Pittsburgh School of Medicine
Director, Division of Allergy, Asthma and Immunology
Pediatric Alliance
University of Pittsburgh Medical Center
Pittsburgh, PA
Overview
Using the latest evidence related to the safety, efficacy, and tolerability profiles of current treatment options, combined with improved skills in recognition and diagnosis, physicians can be poised to deliver up-to-date, evidence-based care to their patients with ADHD.
Objectives
Recognize the importance of early identification of symptoms for improved diagnosis and treatment of children and adolescents with ADHD
Compare and contrast the current treatment options for children and adolescents with ADHD and develop individualized management strategies for each patient
Faculty
David Baron, MSEd, DO
Professor and Chair, Department of Psychiatry and Behavioral Sciences, Temple University School of Medicine
Philadelphia, PA
Frank A. Lopez, MD
Neuro-Developmental Pediatrician
Director, ChildrenŐs Developmental Center
Winter Park, FL
Overview
One in 152: autism affects more children than diabetes, cancer, and AIDS combined. While there is no cure for autism, early diagnosis and intensive treatment significantly increases the chances of the child leading an active and full life. Autism Spectrum Disorders (ASD), on the rise globally, challenges the primary care clinicians to make an early diagnosis with proper screening tools. This program will provide the latest information on ASD and facilitate early diagnosis to improve the long-term outcome for the child, their family, and community.
Objectives
Identify the criteria and specific symptoms of ASD for early diagnosis
Identify screening tools for ASD and administer them to patients with possible developmental delays
Faculty
Marilyn Augustyn, MD
Division Director
Developmental and Behavioral Pediatrics
Boston Medical Center
Boston MA